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Computational Methods Emerging as 
Central to the Scientific Enterprise
1.enormous, and increasing, amounts of data collection,
• ~3TB/yr genome sequence data:  ~1000 sequencers running full time producing 
600GB each run (HiSeq 2000, 11 days per run),
• CMS project at LHC: 300 “events” per second, 5.2M seconds of runtime per 
year, .5MB per event = 780TB/yr => several PB when data processed,
• Sloan Digital Sky Survey: 8th data release (2010), 49.5TB.
2.massive simulations of the complete evolution of a physical system, 
systematically varying parameters,
3.deep intellectual contributions now encoded in software.
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Updating the Scientific Method
Donoho and others have argued that computation 
presents only a potential third branch of the scientific 
method:
- Branch 1  (deductive): mathematics, formal logic,
- Branch 2  (empirical): statistical analysis of 
controlled experiments,
- Branch 3? (computational): large scale simulations.
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The Ubiquity of Error
• The central motivation for the scientific method is to root out error:
- Deductive branch: the well-defined concept of the proof, 
- Empirical branch: the machinery of hypothesis testing, structured 
communication of methods and protocols.
• Computational science as practiced today does not generate reliable 
knowledge.
• See e.g. Ioannidis, “Why Most Published Research Findings are False,” 
PLoS Med, 2005.
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Computation Emerging as Central 
to the Scientific Endeavor
JASA June Computational Articles Code Publicly Available
1996 9 of 20 0%
2006 33 of 35 9%
2009 32 of 32 16%
2011 29 of 29 21%
• Data and code typically not made available at the time of scientific 
publication, rendering results unverifiable, not reproducible.
➡ A Credibility Crisis
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Duke Clinical Trials Case
• Potti et al (2006), Nature Medicine; (2006) NEJM; (2007) 
Lancet Oncology; (2007) Journal of Clinical Oncology: 
evidence of genomic signatures to guide use of 
chemotheraputics (all since retracted),
•Coombes, Wang, Baggerly at M.D. Anderson Cancer Center 
cannot replicate, and find simple flaws: genes misaligned by 
one row, column labels flipped, genes repeated and missing 
from analysis..
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Correcting the Flaws
• 2007 correspondence and a supplementary report submitted 
to the Journal of Clinical Oncology - publication declined; 
2008 Nature Medicine declines to publish correspondence.
•Clinical trials initiated in 2007 (Duke), 2008 (Moffitt).
•Duke launches internal investigation Sept 2009; all three trials 
suspended in Oct 2009,
•Oct 2009: results reported validated, regardless of errors, 
because data blinded (later found not to be true),
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Clinical Trials?
• Jan 2010: Duke clinical trials resume, patients allocated to 
treatment and control groups. “Neither the review nor the raw 
data are being made available at this time.”
• July 2010: 33 prominent biostatisticians write to Harold Varmus as 
NCI Director urging suspension of the trials and an examination 
of standards of review, including reproducibility.
• Sept 2010: IOM committee “Review of Omics-Based Tests for 
Predicting Patient Outcomes in Clinical Trials” formed,
•Nov 2010: Potti resigns and the clinical trials are terminated.
Tuesday, September 20, 2011
Excerpt: Letter to Varmus
“We strongly urge that the clinical trials in question ... be suspended 
until a fully independent review is conducted of both the clinical trials 
and of the evidence and predictive models being used to make cancer 
treatment decisions.  For this to happen, sufficiently detailed data and 
annotation must be made available for review. The data should be 
sufficiently documented for provenance to be assessed (as both gene 
and sample mislabeling have been documented in these data), and the 
computer code used to predict which drugs are suitable for particular 
patients must be made available to allow an independent group of 
expert genomic data analysts to assess its validity and reproducibility 
using the data supplied.”
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Duke Recent Events
• IOM Committtee meetings, including with Duke representatives on 
August 22, 2011,
• 2 lawsuits filed by patients in the clinical trials, asserting that “that 
Duke's response "to the accusation of invalid and fraudulent science 
was deceptive, misleading, and fraudulent conduct designed to protect 
its reputation and proprietary interests … rather than protecting the 
safety of the patients involved in the clinical trials." This "reduced the 
Plaintiffs' likelihood of surviving his/her cancer or the likelihood of 
experiencing a positive response to the chemotherapy regimen."
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Framing Principle for Scientific 
Communication: Reproducibility
• “The idea is:  An article about computational science in a scientific 
publication is not the scholarship itself, it is merely advertising of the 
scholarship. The actual scholarship is the complete software 
development environment and the complete set of instructions which 
generated the figures.” David Donoho, 1998.
• (simple) definition: a result is reproducible if a member of the field can 
independently verify the result.
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Central Thesis
• Computational science must develop standards for reproducibility 
before it can be considered a third branch of the scientific method,
➡Data and Code sharing with publication.
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The Role of Policy 
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Congress: Bayh-Dole Act
• Bayh-Dole Act (1980), designed to promote the transfer of academic 
discoveries for commercial development, via licensing of patents.
• Legislators blind to the coming digital revolution, impact on software and 
algorithm patenting.  Tech Transfer Offices and code release.
• Implications for science as a disruptor of openness norms:
• patents => delay in revealing code, or closed code,
• I assert Bilski => obfuscation of methods submitted for patents,
• (aside from altering a scientist’s incentives toward commercial ends).
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Congress:  America COMPETES
• America COMPETES Re-authorization (2011):
• § 103: Interagency Public Access Committee:
“coordinate Federal science agency research and policies related to the 
dissemination and long-term stewardship of the results of unclassified 
research, including digital data and peer-reviewed scholarly publications, 
supported wholly, or in part, by funding from the Federal science 
agencies.” (emphasis added)
• § 104: Federal Scientific Collections: OSTP “shall develop policies for the 
management and use of Federal scientific collections to improve the quality, 
organization, access, including online access, and long-term preservation of such 
collections for the benefit of the scientific enterprise.” (emphasis added)
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Funding Agency Policy
• NSF grant guidelines:
“NSF ... expects investigators to share with other researchers, at no more 
than incremental cost and within a reasonable time, the data, samples, 
physical collections and other supporting materials created or gathered in 
the course of the work. It also encourages grantees to share software and 
inventions or otherwise act to make the innovations they embody widely 
useful and usable.”
• NSF peer-reviewed Data Management Plan, January 2011.
• NIH (2003): “The NIH endorses the sharing of final research data to serve 
these and other important scientific goals.  The NIH expects and supports 
the timely release and sharing of final research data from NIH-supported 
studies for use by other researchers.” (>$500,000, include data sharing plan)
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Journal Policy
• Different approaches by journals:
• may offer unreviewed “supplemental materials” section,
• may require data and/or code to be provided upon request 
(Science as of Feb 11 2011),
• may employ an Associate Editor for Reproducibility 
(Biostatistics, Biometrical Journal) or replicate results (ACM 
SIGMOD),
• may publish correspondence from the review process 
(Molecular Systems Biology,  The European Molecular Biology 
Organization Journal),
• new journals, ie. Open Research Computation, BMC Data 
Notes
• ignore the issue entirely..
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Journal Policy: Preliminary Results
• ISI Journal Citation Report
- Impact Factor (citations/articles)
• Fields:
- Mathematical & Computational Biology
- Statistics & Probability
- Multidisciplinary Science
• 176 journals examined, 170 studied
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Groundswell from across the 
Computational Sciences
• AMP 2011 “Reproducible Research:  Tools and Strategies for Scientific Computing”
• AMP / ICIAM 2011 “Community Forum on Reproducible Research Policies”
• SIAM Geosciences 2011 “Reproducible and Open Source Software in the Geosciences”
• ENAR International Biometric Society 2011: Panel on Reproducible Research
• AAAS 2011:  “The Digitization of Science: Reproducibility and Interdisciplinary Knowledge Transfer”
• SIAM CSE 2011:  “Verifiable, Reproducible Computational Science”
• Yale 2009: Roundtable on Data and Code Sharing in the Computational Sciences
• ACM SIGMOD conferences
• NSF/OCI report on Grand Challenge Communities (Dec, 2010)
• IOM “Review of Omics-based Tests for Predicting Patient Outcomes in Clinical Trials”
• ...
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Final Observations
• Reproducibility emerging as a movement, with corollary efforts 
to enable code and data sharing.
• interlocking incentives: federal policy, funding agency policy, 
journal policy, review and tenure committees.
• facilitation of reproducibility through tool development (see 
http://www.stodden.net/AMP2011).
• serious consequences, both in the short term (e.g. clinical trials) 
and in the long term (establishing scientific facts).
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Supplemental Slides
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Legal Barriers: Copyright
• Original expression of ideas falls under copyright by default 
(papers, code, figures, tables..)
• Copyright secures exclusive rights vested in the author to:
- reproduce the work
- prepare derivative works based upon the original
- limited time: generally life of the author +70 years
“To promote the Progress of Science and useful Arts, by securing for 
limited Times to Authors and Inventors the exclusive Right to their 
respective Writings and Discoveries.” (U.S. Const. art. I, §8, cl. 8)
Exceptions and Limitations: Fair Use.
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Responses Outside the Sciences 1: 
Open Source Software
• Software with licenses that communicate alternative terms 
of use to code developers, rather than the copyright 
default.
• Hundreds of open source software licenses:
- GNU Public License (GPL)
- (Modified) BSD License
- MIT License
- Apache 2.0 License
- ... see http://www.opensource.org/licenses/alphabetical
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Responses Outside the Sciences 2: 
Creative Commons
• Founded in 2001, by Stanford Law Professor 
Larry Lessig, MIT EECS Professor Hal Abelson, 
and advocate Eric Eldred.
• Adapts the Open Source Software approach to 
artistic and creative digital works.
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Responses Outside the Sciences 2: 
Creative Commons
• Creative Commons provides a suite of licensing options for digital 
artistic works:
- BY: if you use the work attribution must be provided,
- NC: the work cannot be used for commercial purposes,
- ND: no derivative works permitted,
- SA: derivative works must carry the same license as the original
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Response from Within the Sciences
• A suite of license recommendations for computational science:
• Release media components (text, figures) under CC BY,
• Release code components under Modified BSD or similar,
• Release data to public domain or attach attribution license.
➡ Remove copyright’s barrier to reproducible research and,
➡ Realign the IP framework with longstanding scientific norms.
The Reproducible Research Standard (RRS) (Stodden, 2009)
Winner of the Access to Knowledge Kaltura Award 2008
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Advantages to the RRS
• focus becomes the release of the entire research 
compendium,
• hook for funding agencies, journals, universities,
• standardization avoids license incompatibilities,
• clarity of rights (beyond fair use),
• this IP frameworks supports scientific norms.
Tuesday, September 20, 2011
Barriers to Data and Code Sharing 
in Computational Science
Survey of Machine Learning Community, NIPS (Stodden, 2010):
Code Data
77% Time to document and clean up 54%
52% Dealing with questions from users 34%
44% Not receiving attribution 42%
40% Possibility of patents -
34% Legal Barriers (ie. copyright) 41%
- Time to verify release with admin 38%
30% Potential loss of future publications 35%
30% Competitors may get an advantage 33%
20% Web/disk space limitations 29%
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